Back to Trials
NCT06817408Recruiting

Dynamics of Organ Damage and Immune Exhaustion During Sepsis

Mayo Clinic

Start Date

3/25/2025

Completion Date

12/1/2026

Summary

This is a prospective, non-randomized study investigating if organ damage and immune changes can be measured by liquid biopsy NGS through advanced analytical methods.

Detailed Description

To determine the sample size needed to derive a signature matrix to identify novel biomarkers in sepsis, investigators performed a mathematical modeling exercise of the lower limits of sensitivity of this liquid biopsy approach. The detection limit of cell-free nucleic acid analysis is determined in part by the number of independent transcripts or "reporters" that are interrogated. Using an established and independently validated binomial model that was previously applied to the prediction of circulating tumor nucleic acid detection limits, investigators estimated the probability of cell-free nucleic acid detection in sepsis patients based on the number of unique tissue-specific reporters (i.e., hepatic transcripts that may reflect disease severity). This yields a result of n=18 per group to achieve 0.90 power at alpha=0.05. The investigators will thus plan to analyze data from n=18 per cell/tissue type to derive the signature matrix for this project.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: • Patients who've developed a shocked state (Hypotension or Lactate grade \>4) or Clinical Concern Exclusion Criteria: * \<18 years of age * Pregnant Women * Nursing women

Interventions

OTHER

Observation

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Sepsis

Locations

Mayo Clinic Rochester

Rochester, Minnesota 55905

United States